MELBOURNE, AUSTRALIA--(MARKET WIRE)--Jun 6, 2007 -- Prana Biotechnology Limited (NasdaqCM:PRAN - News) (ASX:PBT.AX - News), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, announced today that it will present new data on Prana’s lead Alzheimer’s disease (AD) drug PBT2 at the Alzheimer’s Association International Conference on Prevention of Dementia, in Washington D.C.